Navigation Links
Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
Date:12/3/2012

hat could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements include, among others, our inability to timely commence or complete the clinical trials consistent with our current expectations and our inability to successfully develop, receive regulatory approvals for or to commercialize a new product candidate to prevent C. diff infection and other factors described in Synthetic Biologics' report on Form 10-K/A for the year ended December 31, 2011 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

1 GlobalData. Beta-lactam Antibiotics Sales - United States of America, 2011. Prepared for Synthetic Biologics, Inc. November 2012.

2 Agency for Healthcare Research and Quality. Healthcare and Cost Utilization Project. Statistical Brief #124. Clostridium difficile Infections (CDI) in Hospital Stays, 2009. January 2012. Available at http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
3. Synthetic Biologics Reports Second Quarter 2012 Financial Results
4. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
5. The Use of New Replikins Synthetic Vaccines to Prevent Pandemics to be Presented at Influenza Congress Nov. 12 in Washington DC
6. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
7. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
8. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
9. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
10. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
11. Chinese Compulsory Immunization Program for Livestock Creates Massive Opportunity for Animal Vaccines and Biologics Developers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Boehringer Ingelheim Pharmaceuticals, Inc. today announced its pipeline ... 2 diabetes therapeutic area. The Company is investigating ... worldwide. New Phase II data results for linagliptin ... the Company,s lead diabetes compound, were presented today at ...
... , Two-year study presented at the American Diabetes ... to standard insulin therapy in pulmonary function tests ... AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is ... in pulmonary function tests comparable to usual antidiabetic ...
Cached Medicine Technology:Boehringer Ingelheim Unveils Diabetes Pipeline 2Boehringer Ingelheim Unveils Diabetes Pipeline 3Boehringer Ingelheim Unveils Diabetes Pipeline 4Boehringer Ingelheim Unveils Diabetes Pipeline 5AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA 2AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA 3
(Date:7/10/2014)... In his latest blog post at http://www.perwickstrom.com , ... Wickstrom has listed 5 ways to follow-up without being ... get information or sometimes even just return an inquiry, ... a skill that most people don’t have,” commented Per ... dialogue moving without coming across as annoying – let ...
(Date:7/10/2014)... New York (PRWEB) July 10, 2014 ... dedicated to protecting the rights of victims injured ... has brought a lawsuit over allegations that the ... body by a power morcellator used during a ... been filed against Richard Wolf Medical Instruments Corporation ...
(Date:7/10/2014)... widespread across the United States, due in large to ... of clinical data that will become available for research ... experts in healthcare have become increasingly focused on clinical ... purpose of gleaning insights that have the potential to ... that is known as big data. ...
(Date:7/10/2014)... News) -- Adults with dyslexia are more likely to ... teenagers than people who don,t have the learning disorder, ... affects up to 10 percent of people, causes problems ... of adults with this condition said they suffered physical ... those without dyslexia. "Even after accounting for age, ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Men who have a vasectomy ... a new study suggests. But the risk is ... involved with the study said more research is needed ... For the study, Harvard researchers analyzed data from ... 24 years, starting in 1986. During that time, 6,023 ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3
... development of high performance HEK293, (human) production cell lines ... ... 16 Selexis SA, a Swiss-based biotechnology,company offering DNA ... discovery, development, and cGMP production of,biologics, announced today it ...
... C.V (BMV: LAB) announces the following Webcast:, What: Second ... 12:00 pm Eastern Time, ... Live over the Internet -- Simply log on to the ... above., Contact: Maria Barona of i-advize Corporate Communications, Inc., ...
... In two complementary studies, Weizmann Institute scientists have developed ... and have applied this technique to trace the history ... understand a cell,s path of descent, called a cell ... and medicine as gleaning such knowledge is key to ...
... developed a potential new treatment against cancer that attaches magnetic ... carried out of the body. The treatment, which has ... at in survival studies, is detailed online in the ... able to use magnetic nanoparticles to capture free-floating cancer cells ...
... threats like heart attack and stroke , , WEDNESDAY, July 16 ... high blood pressure -- more than 73 million adults. , ... in controlling their blood pressure. , For instance, women with ... have high cholesterol levels. They,re also less likely than men ...
... a leader in health,care quality management solutions for ... Gregory A. Buchholz to the newly created,position of ... will be,responsible for all aspects of operations at ... project management,informatics, data processing and information technology departments. ...
Cached Medicine News:Health News:Selexis Now Offering Rapid-Development of Human Cell Line With FDA Approval Pedigree 2Health News:Weizmann Institute scientists' new technique gets to the root of cancer 2Health News:Weizmann Institute scientists' new technique gets to the root of cancer 3Health News:Using magenetic nanoparticles to combat cancer 2Health News:Many Women Struggle With Uncontrolled Blood Pressure 2Health News:Many Women Struggle With Uncontrolled Blood Pressure 3Health News:Many Women Struggle With Uncontrolled Blood Pressure 4Health News:MDdatacor Names Gregory Buchholz Chief Operating Officer 2
... CC 527 is an assayed quality control material ... electrolyte, and CO-Oximeter instrumentation. It is for specific ... and hemoglobin fractions (280, 288, and 270) and ... 527 may also be used on the IRMA ...
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
For the qualitative detection of igG antibodies specific to Helicobacter pylori in human serum, plasma and whole blood specimens...
Medicine Products: